Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-23

Clinical Trial Update: Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tributyrin supplementation in Parkinson's disease was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tributyrin (tributyrin)

Snippet

Sponsor: Nicolaas Bohnen, MD, PhD | Conditions: Parkinson Disease | Phase 1 | Status: TERMINATED | Results posted: 2025-01-23